01
The trials studied pattern hair loss
The headline evidence applies to androgenetic or female-pattern hair loss, not every reason hair may thin. Sudden shedding, patches, inflammation, scarring, postpartum loss and nutritional or medication-related changes were not all interchangeable with the trial populations.
That is why product choice should follow a plausible diagnosis. An objective increase in a target-area count is evidence of an average treatment effect, but it does not predict the visibility of regrowth for one person or guarantee the same response across the whole scalp.
02
The men's 48-week trial showed a concentration effect
Olsen and colleagues randomized 393 men aged 18 to 49 to twice-daily 5% solution, 2% solution or vehicle for 48 weeks. Mean non-vellus hair-count increases were approximately 18.6, 12.7 and 3.9 hairs per square centimeter, respectively.
The paper described the 5% group as producing 45% more regrowth than 2% at week 48 and responding earlier. Dermatologic symptoms such as itching or contact dermatitis were reported more often with 5% than 2%, while no systemic-effect signal emerged in this selected trial population.
03
Women's trials confirm benefit but not a simple winner
A 48-week trial randomized 381 women to 5%, 2% or vehicle. Five percent beat placebo on hair count and both patient and investigator endpoints. Two percent beat placebo for hair count and investigator assessment, but not for patient-rated growth; irritation and unwanted hair growth were more common with 5%.
A later phase III trial compared once-daily 5% foam with twice-daily 2% solution in 322 women. At week 24, adjusted target-area gains were nearly identical: 23.9 versus 24.2 hairs per square centimeter. Formal noninferiority was not established because the confidence interval crossed the prespecified margin.
04
Timeline, maintenance and safety belong beside efficacy
Benefits require ongoing use, and early shedding, local irritation or unwanted facial hair can occur. Formulation labels differ, so a general evidence article should not turn one study schedule into dosing advice for every reader.
The official women's 5% foam label says not to self-treat sudden, patchy or unexplained loss, and to stop use and contact a doctor if chest pain, a rapid heartbeat, faintness, dizziness, sudden weight gain, swelling or significant scalp irritation occurs. Chest pain or fainting may require urgent care. The label also warns that use may be harmful during pregnancy or breastfeeding; a clinician can assess whether the diagnosis and formulation fit the person.
Direct sources
Read the research
- Olsen et al. — 5% versus 2% minoxidil and placebo in male pattern hair loss ↗Journal of the American Academy of Dermatology (2002), PMID 12196747, DOI 10.1067/mjd.2002.124088
- Lucky et al. — 5% and 2% topical minoxidil in female pattern hair loss ↗JAAD (2004), PMID 15034503, DOI 10.1016/j.jaad.2003.06.014
- Blume-Peytavi et al. — Once-daily 5% foam versus twice-daily 2% solution ↗Journal of Drugs in Dermatology (2016), PMID 27391640
- FDA — Women's 5% minoxidil topical aerosol label ↗Official product labeling with indications, warnings and use limitations
Editorial transparency
This article was prepared by the HairstyleChange Research Desk from the cited sources. It has not been presented as medical review by a named clinician. Corrections and qualified reviewer enquiries are welcome through our contact page.
How we research and correct articles ↗